Can Zetia Cause Tachycardia?
No, tachycardia is not a recognized adverse effect of ezetimibe (Zetia) based on FDA labeling, major clinical guidelines, or high-quality clinical trials.
Evidence from FDA Drug Labeling
The official FDA prescribing information for Zetia does not list tachycardia or any cardiac rhythm disturbances among its adverse effects 1. The most commonly reported adverse reactions (≥2% incidence) in clinical trials include 1:
- Upper respiratory tract infection (4.3%)
- Diarrhea (4.1%)
- Arthralgia (3.0%)
- Sinusitis (2.8%)
- Pain in extremity (2.7%)
When combined with statins, the most common adverse reactions were nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, and diarrhea—again, with no mention of tachycardia 1.
Clinical Trial Safety Data
Major cardiovascular outcomes trials have not identified tachycardia as an adverse event associated with ezetimibe. The 2022 ACC Expert Consensus document notes that adverse effects from ezetimibe monotherapy include upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in extremities, but does not mention any cardiac arrhythmias 2.
A comprehensive Cochrane systematic review of 26 randomized controlled trials involving 23,499 participants found that ezetimibe has little or no difference in adverse event profiles compared to placebo, with the main concerns being hepatopathy and myopathy—not cardiac rhythm disturbances 3.
Real-World Safety Surveillance
A 2024 analysis of the FDA Adverse Event Reporting System (FAERS) database covering 2004-2023 identified 211 preferred terms across 24 system organ classes for ezetimibe 4. While this study noted unstable angina and rhabdomyolysis as signals, tachycardia was not identified as a significant adverse event 4.
An Australian pharmacovigilance study examining ezetimibe use from 2004-2015 found that the major reported adverse events were musculoskeletal and connective tissue disorders and gastrointestinal disorders, with no mention of tachycardia 5.
Paradoxical Anti-Arrhythmic Properties
Interestingly, emerging research suggests ezetimibe may actually have anti-arrhythmic properties rather than pro-arrhythmic effects. A 2021 study demonstrated that ezetimibe enhances mitochondrial calcium uptake and suppresses cardiac arrhythmogenesis in models of catecholaminergic polymorphic ventricular tachycardia 6. This suggests that if anything, ezetimibe may protect against rather than cause arrhythmias.
Clinical Bottom Line
If a patient on ezetimibe develops tachycardia, look for alternative explanations such as:
- Underlying cardiovascular disease progression
- Concomitant medications (particularly if combined with statins)
- Other medical conditions (hyperthyroidism, anemia, infection)
- Anxiety or other non-cardiac causes
The extensive clinical trial database, FDA labeling, and post-marketing surveillance do not support a causal relationship between ezetimibe and tachycardia 1, 3.